The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy
about
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.Induction of apoptosis and proliferation inhibition of hepatocellular carcinoma by 6-chloro-2-methoxy-N-(phenylmethyl)-9-acridinamine (BA): in vitro and vivo studies.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinomaSulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal modelAssessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway.Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activationChemoinformatics in the New Era: From Molecular Dynamics to Systems Dynamics.Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolizationMechanisms of doxorubicin resistance in hepatocellular carcinomaE4BP4 is an insulin-induced stabilizer of nuclear SREBP-1c and promotes SREBP-1c-mediated lipogenesis.A PTEN inhibitor displays preclinical activity against hepatocarcinoma cellsErgosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cellsVertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma.Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation.Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.Phosphorylated AKT expression in tumor-adjacent normal tissue is associated with poor prognosis in patients with hepatocellular carcinoma.Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.Targeting autophagy in chemotherapy-resistant of hepatocellular carcinoma.
P2860
Q33688897-F5F2B5D5-47F5-4E80-9E51-C7944C870C58Q33868747-2154A15C-3423-42B2-A417-74307BBED6FDQ33917547-005546B7-3093-4855-8810-B016851FA8DEQ33977001-023E433F-24CD-46DE-AD94-57D9D4705463Q34104125-F0022EBC-1552-4659-93F3-378283A45F53Q34365926-F5353D7F-CA59-4CDC-8ABC-5339392DA57DQ34957330-183C335D-6393-4C5E-A7D8-2EAEFDDD4A82Q35833001-9C2954F9-1427-4138-96EE-9D5D03E370ACQ35947657-629C3A36-AF62-4E5E-BB14-C1A30BECF5B2Q36414381-177F9F11-1817-4BB1-A499-FADD260B36DFQ36619130-9FDAF037-5A70-4D39-A987-A13B7696D594Q36687760-900DFCB1-D93F-48CA-9736-03981C8E943AQ37033133-317E2112-59C0-4797-9DDC-04E7DFD6C62EQ37324522-707AED72-3188-46B5-BFEF-FE6C4D68DCF0Q37376175-D043BE22-B645-4511-A842-D93625CAC86BQ37641562-84B91668-A2A2-469B-813F-5950A0E93A17Q38862452-64FAE2C8-6F10-43B7-AF93-DEAD18466BDEQ38871688-45F757E7-F47D-42A0-9D6D-75D0BE5D6E75Q38946509-80B93B88-55B2-4323-96DA-F783C01D58B4Q38949674-FBCAECAD-7EA1-4CB1-9ED2-F56C86E1E519Q42128983-3FBA0A98-EAF1-4776-82B3-EA8D204E86E5Q42317505-5C6E35CE-D1B3-4BE1-8597-763313B66DF2Q42440865-80A30DF5-4553-4E67-B851-36CD711DE88EQ47094892-8BFD9F8F-1452-4282-BF63-6BEF7323185CQ47110143-EE31E96F-C84F-4402-9484-02BD8A255846Q47552146-D68CC153-8198-41E7-BEAE-0D8B65294284Q51474050-D3A1B742-D341-42A2-9411-17532AD363B4Q53696566-BD3A1E08-848A-4EAA-B753-D8166BE3934B
P2860
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The AKT inhibitor MK-2206 is c ...... with conventional chemotherapy
@en
The AKT inhibitor MK-2206 is c ...... ith conventional chemotherapy.
@nl
type
label
The AKT inhibitor MK-2206 is c ...... with conventional chemotherapy
@en
The AKT inhibitor MK-2206 is c ...... ith conventional chemotherapy.
@nl
prefLabel
The AKT inhibitor MK-2206 is c ...... with conventional chemotherapy
@en
The AKT inhibitor MK-2206 is c ...... ith conventional chemotherapy.
@nl
P2093
P2860
P356
P1433
P1476
The AKT inhibitor MK-2206 is c ...... with conventional chemotherapy
@en
P2093
Alberto M Martelli
Carolina Simioni
James A McCubrey
Luca M Neri
Rengul Cetin-Atalay
P2860
P304
P356
10.18632/ONCOTARGET.1236
P407
P577
2013-09-01T00:00:00Z